{"entity":{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","aka":[],"tldr":"Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.","summary":"Amod A. Sarnaik is a Surgical Oncologist in Cutaneous Oncology and a Senior Member at Moffitt Cancer Center, specialising in melanoma surgery and cellular immunotherapy. He is known as principal investigator of C-144-01, the pivotal trial of lifileucel that produced the first approved tumour-infiltrating lymphocyte therapy, with accelerated approval in advanced melanoma in 2024. His selected paper reports lifileucel, a tumour-infiltrating lymphocyte therapy, in metastatic melanoma. He continues to combine melanoma surgery with the development of TIL therapy at Moffitt.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/amod-sarnaik/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sarnaik%20AA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":["c-144-01"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical Oncologist, Cutaneous Oncology; Senior Member","institutionId":"moffitt","specialisms":["Melanoma surgery","TIL therapy","Cellular immunotherapy"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/amod-sarnaik/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sarnaik%20AA%5BAuthor%5D"}],"papers":[{"title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/JCO.21.00612","doi":"10.1200/JCO.21.00612"},{"title":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","journal":"Journal of Clinical Oncology","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=C-144-01%20lifileucel%20tumor-infiltrating%20lymphocyte%20melanoma%20Sarnaik%20JCO%202021"}],"orcid":"0000-0002-2337-5898"},"route":"/people/amod-sarnaik/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"institution":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/"}],"trial":[{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/"}],"paper":[{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/"}]}}